{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:07:09Z","timestamp":1791191229760,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,5,17]],"date-time":"2005-05-17T00:00:00Z","timestamp":1116288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Antibody\u2010mediated rejection (AMR) has recently been recognized as a significant and unique form of rejection that is not amenable to treatment with standard immunosuppressive medications aimed at modification of T\u2010cell function. Recent interest in AMR and the role of B cells in rejection has been aided by the concomitant discovery that C4d staining of renal biopsy tissue is strongly associated with AMR and a poor prognosis, and the emergence of desensitization protocols for treatment of highly human leukocyte antigen (HLA)\u2010sensitized patients. Treatment options include: (i) the use of high\u2010dose intravenous immunoglobulin (IVIG) which works by blocking anti\u2010HLA antibody activity and through complement inhibition, (ii) the use of Rituxan (anti\u2010CD20 chimeric antibody) to deplete B cells and interfere with antigen\u2010presenting cell (APC) activity of B cells subsequently decreasing T\u2010cell activation, and (iii) the use of plasmapheresis (PE)\u2003+\u2003anti\u2010cytomegalovirus (CMV) immunoglobulin G (IgG) or IVIG in lower doses. This protocol removes deleterious anti\u2010HLA antibodies and may also allow complexing of anti\u2010HLA with anti\u2010idiotypes in the anti\u2010CMV IgG. Although early, data support the efficacy of all three approaches. Many centers are now designing protocols that utilize a combination of all three agents. In summary, recent advances in the diagnosis and treatment of AMR has allowed for significant improvements in outcomes of a condition usually associated with rapid graft failure. However, much work needs to be done to better understand the immunologic processes leading to AMR and how current therapies can be best used to effectively prevent and treat it.<\/jats:p>","DOI":"10.1111\/j.1399-3046.2005.00363.x","type":"journal-article","created":{"date-parts":[[2005,5,17]],"date-time":"2005-05-17T09:25:31Z","timestamp":1116321931000},"page":"408-415","source":"Crossref","is-referenced-by-count":85,"title":["Current approaches to treatment of antibody\u2010mediated rejection"],"prefix":"10.1111","volume":"9","author":[{"given":"Stanley C.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Tyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C.","family":"Nast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieko","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,5,17]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196904032801401"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199902150-00008"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000129256.84027.D6"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00500.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1681\/ASN.V1341091","article-title":"Capillary C4d deposition in kidney allografts: a specific marker of alloantibody\u2010dependent graft injury","volume":"13","author":"Bohmig GA","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00072.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200009270-00006"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200011270-00023"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199402270-00014"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00121.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00454.x"},{"key":"e_1_2_8_13_2","first-page":"258","article-title":"Anti\u2010CD20 rescue therapy for kidneys undergoing antibody\u2010mediated rejection (abstract)","volume":"4","author":"Montgomery R","year":"2004","journal-title":"Am J Transplant"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360"},{"key":"e_1_2_8_15_2","first-page":"803","article-title":"Intravenous gamma globulin (IVIG) inhibits lymphocytotoxic antibody in vitro","volume":"2","author":"Jordan SC","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_8_16_2","first-page":"887","article-title":"Intravenous immunoglobulin (IVIg) reduces antibody responses in highly sensitized dialysis patients","volume":"3","author":"Yadin O","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_8_17_2","first-page":"1038","article-title":"Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins","volume":"27","author":"Glotz D","year":"1995","journal-title":"Transplant Proc"},{"key":"e_1_2_8_18_2","article-title":"Intravenous immunoglobulins and transplantation for patients with anti\u2010HLA antibodies","author":"Glotz D","year":"2003","journal-title":"Transpl Int"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199609150-00027"},{"key":"e_1_2_8_20_2","first-page":"360","article-title":"Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient","volume":"16","author":"De Marco T","year":"1997","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199809270-00017"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200101150-00009"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200108150-00010"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000145878.92906.9F"},{"key":"e_1_2_8_25_2","first-page":"256","article-title":"A four year follow up of rejection patterns, treatment and outcomes in highly\u2010HLA sensitized crossmatch positive patients transplanted with IVIG desensitization (abstract)","volume":"4","author":"Jordan SC","year":"2004","journal-title":"Am J Transplant"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00101.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00180.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000060252.57111.AC"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000122187.76518.BC"},{"key":"e_1_2_8_30_2","article-title":"A hyperimmune anti\u2010cytomegalovirus immunoglobulin (Cytogam\u00ae) induces apoptosis in B\u2010cells, inhibits the MLR and immunoglobulin production in vitro to a degree similar to or greater than pooled polyclonal gamma globulin (IVIG)","volume":"5","author":"Toyoda M","year":"2005","journal-title":"Am J Transplant"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_8_36_2","first-page":"2580","volume-title":"Arthritis Rheum","author":"Looney RJ","year":"2004"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10764"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.883"},{"key":"e_1_2_8_39_2","first-page":"187","article-title":"The use of Rituximab in 28 adults with chronic immune thrombocytopenic purpura (ITP)","volume":"22","author":"Feuerstein M","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402676"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000080685.31697.FC"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(02)03824-9"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01533367"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.8.3325"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5503.484"},{"key":"e_1_2_8_46_2","first-page":"269","article-title":"Anti\u2010CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg)","volume":"1","author":"Hurez V","year":"1994","journal-title":"Ther Immunol"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118297"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1530"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01499.x"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90563-V"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00011.x"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3046.2005.00363.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3046.2005.00363.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:27:17Z","timestamp":1696904837000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3046.2005.00363.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,17]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1111\/j.1399-3046.2005.00363.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3046.2005.00363.x","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"value":"1397-3142","type":"print"},{"value":"1399-3046","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,17]]}}}